





# Financial Report

Board of Trustees Meeting July 25, 2024



#### Overview

The Board's actions over the last year have stabilized the budget situation through 2025.

More action is needed to resolve a structural deficit going forward.

- FY 2023-24 Estimated Actual vs. Budget
- CY 2024 Projection vs. Budget
- FY 2024-25 Budget
- CY 2025 Budget
- Projections for CY 2026-27
- Strategies for Balancing the Budget



# Projection vs. Budget: Fiscal Year 2023-24

(\$s in millions)	FY 2023-24 Est. Actual	FY 2023-24 Budget	Difference
Premiums & Subsidies	\$4,105.1	\$4,141.3	(\$36.2)
Investment Earnings	\$30.5	\$5.5	\$25.0
Total Revenue	\$4,135.6	\$4,146.8	(\$11.2)
Net Medical Claims	\$3,087.4	\$3,064.5	\$22.9
Net Pharmacy Claims	\$1,000.2	\$1,020.9	(\$20.7)
Medicare Advantage Payments	\$15.4	\$16.9	(\$1.5)
Administrative Expenses	\$138.8	\$145.6	(\$6.8)
Total Expenses	\$4,241.9	\$4,247.9	(\$6.0)
Plan Income/(Loss)	(\$106.3)	(\$101.1)	(\$5.2)
Ending Cash Balance	\$636.1	\$645.9	(\$9.8)

Budget reflects revised employer contribution rates but has not been adjusted for the exclusion of weight-loss GLP-1s.

# Projection vs. Budget: Calendar Year 2024

(\$s in millions)	CY 2024 Projection	CY 2024 Budget	Difference
Premiums & Subsidies	\$4,300.7	\$4,282.5	\$18.2
Investment Earnings	\$25.5	\$23.2	\$2.3
Total Revenue	\$4,326.2	\$4,305.7	\$20.5
Net Medical Claims	\$3,257.0	\$3,244.0	\$13.0
Net Pharmacy Claims	\$992.8	\$984.1	\$8.7
Medicare Advantage Payments	\$15.5	\$18.5	(\$3.0)
Administrative Expenses	\$140.8	\$138.0	\$2.8
Total Expenses	\$4,406.2	\$4,384.6	\$21.6
Plan Income/(Loss)	(\$80.0)	(\$78.9)	(\$1.1)
Ending Cash Balance	\$591.0	\$590.4	\$0.6

Budget has been adjusted for the exclusion of weight-loss GLP-1s.



### State Health Plan Budget

- The Plan must budget on both a fiscal year and calendar year basis.
- Staff develop the Plan's budget using projections of revenue and expenses in consultation with the Plan's external actuaries.
- Budget Assumptions:
  - No changes to benefits or premiums, except changes that have been approved by the Board.
  - Employer contribution rate = maximum allowed in State budget
- The Board requires the Plan's budget to maintain a year-end cash balance that exceeds the Target Stabilization Reserve (TSR).

TSR = 9% of Calendar Year Claims

~\$390M



#### Reserve Adequacy

- The Target Stabilization Reserve (TSR) is an estimate of the minimum amount the Plan needs to pay for services already provided to its members.
- TSR is the minimum amount the Plan needs to manage typical variations in cash flow.
- Additional reserves may be appropriate:
  - To support long-term financial planning and to avoid the need for sudden changes in response to financial pressures, ensuring benefits remain stable and reliable.
  - To provide cushion due to uncertainty in forecast during times of transition.
  - To manage the inherent unpredictability in healthcare costs.




#### **Budget Monitoring and Adjustments**

- In recent history, the Plan has maintained significant reserves. As reserves decrease, it becomes critical to more closely monitor the budget and actual spending by:
  - Adjusting the budget to reflect:
    - Modifications to employer contribution rates.
    - Board actions related to benefits, premiums, or significant contracts.
    - Major legislative or federal policy changes.
  - Updating financial projections quarterly to reflect current conditions by incorporating enrollment and claims experience.
  - Monitoring and responding to variances between budgeted and actual figures promptly.
  - Managing significant volatility in timing by adjusting actuals to reflect the timing assumptions of the budget to allow for meaningful comparisons.



#### Seasonal Variation and Volatility



#### New Budget: Fiscal Year 2024-25

(\$s in millions)	FY 2024-25 Budget	Change from Prior Year	% Change from Prior Year
Premiums & Subsidies	\$4,393.2	\$220.5	5.3%
Investment Earnings	\$22.5	(\$8.0)	-26.2%
Total Revenue	\$4,415.7	\$212.5	5.1%
Net Medical Claims	\$3,361.0	\$273.6	8.9%
Net Pharmacy Claims	\$991.1	(\$9.1)	-0.9%
Medicare Advantage Payments	\$46.6	\$31.2	202.6%
Administrative Expenses	\$168.0	\$29.2	21.0%
Total Expenses	\$4,566.6	\$324.7	7.7%
Plan Income/(Loss)	(\$151.0)	(\$112.4)	291.2%

Change from prior year is measured relative to an estimate with adjustments for timing.

**Ending Cash Balance = \$554.2M** 

**\$162.5M above TSR** 





### New Budget: Calendar Year 2025

(\$s in millions)	Calendar 2025 Budget	Change from Prior Year	% Change from Prior Year
Premiums & Subsidies	\$4,489.0	\$188.3	4.4%
Investment Earnings	\$20.1	(\$5.4)	-21.2%
Total Revenue	\$4,509.1	\$182.9	4.2%
Net Medical Claims	\$3,377.5	\$120.5	3.7%
Net Pharmacy Claims	\$1,009.5	\$16.7	1.7%
Medicare Advantage Payments	\$91.0	\$75.5	487.1%
Administrative Expenses	\$175.2	\$34.4	24.4%
Total Expenses	\$4,653.1	\$246.9	5.6%
Plan Income/(Loss)	(\$144.0)	(\$64.0)	80.0%

**Ending Cash Balance = \$447.0M** 

\$52.2M above TSR





#### **Forecast Uncertainty**

- New TPA Transition: Significant uncertainty in estimating claims savings.
  - Variations in claims adjudication processes and policies between the old and new TPA can lead to unexpected costs or savings.
  - Uncertainty in achieving anticipated savings through new provider contracts and renegotiations.
  - Changes in member behavior and utilization patterns under the new TPA could affect projected savings.
- Medicare Advantage Premiums: Future rates are unpredictable due to regulatory changes and market dynamics.
- Pharmacy Benefit Volatility: Rapid changes in the sector, such as increasing specialty drug prices, growth of biosimilars, shifting PBM practices, and the introduction of new treatments, increase risk of forecast inaccuracies.




#### Beyond 2025: Out-Year Forecast

- Projections for future years are based on the following key assumptions:
  - State Funding: 4% increase annually, determined on fiscal year basis
  - Annual Per-Member Costs: Projected using customized actuarial trend assumptions
    - Medical Claims: 6.0%
    - Pharmacy Claims: 9.5%
    - Pharmacy Rebates: 7.0%
    - Administrative expenses: 3.0%
  - Medicare Advantage Premiums: Increase from current \$0 rate to \$159 by 2027, based on preliminary renewal estimates.
  - Investment return rate: 3.8%, based on recent experience.
  - Enrollment and plan selection: Various assumptions based on recent enrollment and migration patterns.




#### Impact of 2025 Contribution Adjustments on Projections



- Board voted in June to adjust funding for 2025:
  - Increase Retirement System contribution.
  - Increase premiums for dependents and contributory retirees who elect Medicare Advantage plans.
- Brought projected cash balance at end of CY 2025 to just above TSR.
- Only increased funding for CY 2025.




## Impact of Other Adjustments on Projections



- Projection improved due to:
  - Higher interest rate assumption
  - Slightly lower expected claims expenses.
- Cash balance now expected to exceed TSR by \$52 million at end of 2025.
- Cash balance expected to fall below TSR in early 2026.
- Without action, likely to be unable to pay bills in fall 2026.




#### Revised Projection: Financial Results by Plan Year



### Strategies for Balancing the Budget

- To achieve a balanced budget, the Plan needs a strategic approach that combines increased funding and reduced expenditures.
- At the next Board meetings, we will present detailed options for addressing the budget shortfall.
- The Plan requires approximately \$440 million in 2026 and an additional \$825 million in 2027.



### Strategies for Balancing the Budget

#### Cost Reduction Strategies:

- Work with TPA to secure lower rates through provider network strategy.
- Develop approaches to better differentiate between plans.
- Use data to manage and reduce pharmacy benefit costs.
- Review existing contracts for cost-saving opportunities.

#### • Additional Funding Opportunities:

- Request increase in employer contribution rates from General Assembly
- Request additional reimbursements for over \$316 million in unreimbursed COVIDrelated costs.
- Obtain higher federal subsidies by reopening the Employer Group Waiver Plan (EGWP) for Medicare retirees and maximizing Retiree Drug Subsidies (RDS).

